Decrease in β-Cell Mass Leads to Impaired Pulsatile Insulin Secretion, Reduced Postprandial Hepatic Insulin Clearance, and Relative Hyperglucagonemia in the Minipig
Authors:
Open Access
- 1 September 2001
- journal article
- Published by American Diabetes Association in Diabetes
- Vol. 50 (9) , 2001-2012
Abstract
Most insulin is secreted in discrete pulses at an interval of ∼6 min. Increased insulin secretion after meal ingestion is achieved through the mechanism of amplification of the burst mass. Conversely, in type 2 diabetes, insulin secretion is impaired as a consequence of decreased insulin pulse mass. β-cell mass is reported to be deficient in type 2 diabetes. We tested the hypothesis that decreased β-cell mass leads to decreased insulin pulse mass. Insulin secretion was examined before and after an ∼60% decrease in β-cell mass achieved by a single injection of alloxan in a porcine model. Alloxan injection resulted in stable diabetes (fasting plasma glucose 7.4 ± 1.1 vs. 4.4 ± 0.1 mmol/l; P < 0.01) with impaired insulin secretion in the fasting and fed states and during a hyperglycemic clamp (decreased by 54, 80, and 90%, respectively). Deconvolution analysis revealed a selective decrease in insulin pulse mass (by 54, 60, and 90%) with no change in pulse frequency. Rhythm analysis revealed no change in the periodicity of regular oscillations after alloxan administration in the fasting state but was unable to detect stable rhythms reliably after enteric or intravenous glucose stimulation. After alloxan administration, insulin secretion and insulin pulse mass (but not insulin pulse interval) decreased in relation to β-cell mass. However, the decreased pulse mass (and pulse amplitude delivered to the liver) was associated with a decrease in hepatic insulin clearance, which partially offset the decreased insulin secretion. Despite hyperglycemia, postprandial glucagon concentrations were increased after alloxan administration (103.4 ± 6.3 vs. 92.2 ± 2.5 pg/ml; P < 0.01). We conclude that an alloxan-induced selective decrease in β-cell mass leads to deficient insulin secretion by attenuating insulin pulse mass, and that the latter is associated with decreased hepatic insulin clearance and relative hyperglucagonemia, thereby emulating the pattern of islet dysfunction observed in type 2 diabetes.Keywords
This publication has 50 references indexed in Scilit:
- Direct Measurement of Pulsatile Insulin Secretion from the Portal Vein in Human SubjectsThe Journal of Clinical Endocrinology & Metabolism, 2000
- Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patientsDiabetes, 1991
- Effects of Hemipancreatectomy on Insulin Secretion and Glucose Tolerance in Healthy HumansNew England Journal of Medicine, 1990
- Abnormal Patterns of Insulin Secretion in Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1988
- Impaired Pulsatile Secretion of Insulin in Relatives of Patients with Non-Insulin-Dependent DiabetesNew England Journal of Medicine, 1988
- Islet Pathology and the Pathogenesis of Type 1 and Type 2 Diabetes mellitus RevisitedPathology and Immunopathology Research, 1985
- Cyclic Oscillations of Basal Plasma Glucose and Insulin Concentrations in Human BeingsNew England Journal of Medicine, 1979
- Induction of chronic diabetes by streptozotocin in the miniature pigZeitschrift für Die Gesamte Experimentelle Medizin, 1979
- Hyperglucagonemia and Its SuppressionNew England Journal of Medicine, 1978
- Insulin, Glucagon, and Glucose Exhibit Synchronous, Sustained Oscillations in Fasting MonkeysScience, 1977